Adalimumab biosimilar ABP 501 is equally effective and safe in long-term management of inflammatory bowel diseases patients when used as first biologic treatment or as replace of the ADA originator for a non-medical reason
阿达木单抗生物类似药ABP 501在炎症性肠病患者的长期治疗中，无论作为一线生物制剂治疗，还是因非医疗原因替代阿达木单抗原研药，均具有与原研药相同的疗效和安全性。
期刊:
影响因子:
doi:10.3389/fgstr.2023.1218228
Mocci, Giammarco; Cingolani, Arianna; Orrù, Giorgia; Felice, Carla; Onidi, Francesca Maria; Lombardi, Gianmarco; Checchin, Davide; Colucci, Raffaele; Grossi, Laurino; Ferronato, Antonio; Rocchi, Chiara; Ascolani, Marta; Satta, Paolo Usai; Fanini, Lucia; Pilati, Stefano; Tursi, Antonio
